JM Chapter 23 Flashcards
disorder of iron overload, is the most commot
serious single gene genetic disorder in our population
is a common condition in which the total body iron concentration is increased to 20-60 g
(normal 4 g).
Hereditary haemochromatosis (HHC),
Diagnosis
Hereditary haemochromatosis (HHC)
Increased serum transferrin saturation: >50% (F); >60% (M)
Increased serum ferritin level: >200 mcg/L (F); >300 mcg/L (M)
CT, MRI or FerriScan- increased iron deposition in liver
Liver biopsy (if liver function test enzymes are abnormal or ferritin >1000 mcg/L or
hepatomegaly) FerriScan now preferred
Management of
Hereditary haemochromatosis (HHC)
Weekly venesection 500 mI (250 mg iron) until serum iron stores are normal (may take at
least 2 years), then every 3-4 months to keep serum ferritin level <100 mcg/L (usually
40-80 mcg/L), serum transferrin saturation <50% and iron levels normal
Desferrioxamine can be used but not as effective as venesection
failure to thrive + chronic cough + loose bowel actions -
cystic fibrosis
peripheral neurofibromatosis (von Recklinghausen disorder)
NF1-
central type, bilateral acoustic neuromas (schwannomas) (rare)
NF2-
The gene for NF1 is
carried on chromosome 17 and NF2 on chromosome
light-brown skin patches + skin tumours + axillary freckles
NF1
Clinical features of NF19
Six or more café-au-lait spots (increasing with age)
Freckling in the axillary or inguinal regions
Flesh-coloured cutaneous tumours (appear at puberty)
Hypertension
Eye features (iris
hamartomas)
Learning difficulty
Musculoskeletal problems (e.g. scoliosis, fibrous dysplasia, pseudoarthrosis)
Optic nerve gliomas
is a progressive proximal muscle weakness disorder with replacement of muscle by
connective tissue.
is an X-linked recessive condition. It is caused by a mutation in the gene coding for
dystrophin, a protein found inside the muscle cell membrane.
Duchenne muscular dystrophy (DMD)
Clinical features
Duchenne muscular dystrophy (DMD)
Usually diagnosed from 2-5 years
Weakness in hip and shoulder girdles
Walking problems: delayed onset or starting in boys aged 3-7
Waddling gait, falls, difficulty standing and climbing steps
Pseudohypertrophy of muscles, especially calves
Most in wheelchair by age 10-12
+ Intellectual retardation/learning difficulties
Most die of respiratory problems by age 25
Gower sign: patient uses ‘trick’ method by using hands to climb up his or her legs when rising
to an erect position from the floor
DxT male child + gait
disorder + bulky calves
DMD
Diagnosis
DMD
Elevated serum
creatinine kinase level
Electromyography
Direct dystrophin gene testing
Muscle biopsy
Claimed to be the leading genetic cause of infant death
progressive muscle wasting
due to mutation in SMN1 gene on chromosome 5
Muscle weakness, poor tone and floppiness
Feeding difficullties and fephle crv in hahies
Spinal muscular atrophy (SMA)
Diagnosis of
Spinal muscular atrophy (SMA)
DNA screening at birth and EEG studies.
Treatment of
Spinal muscular atrophy (SMA)
no cure at present and
treatment is mainly supportive. Zolgensma gene therapy is given as a single IV injection into
children <2 years before symptoms appear. Intrathecal injections of nusinersen are available.
Typically presents 20-30 years as myotonia (tonic muscle spasm), occasionally in childhood
Muscle weakness, esp. hands, legs, face, neck
Slow relaxation of hand grip
‘Hatchet face’- long haggard look with atrophy of facial muscles
Frontal baldness in men
Cataracts
Mental impairment
Cardiac disturbances, e.g.cardiomyopathy
Endocrine abnormalities, e.g. diabetes
Myotonic dystrophy
Investigation of
MYOTONIC DYSTROPHY
Electromyography
total deficiency of hexosaminidase resulting in an accumulation of gangliosides in
the brain.
infantile form - fatal by age 3 or 4 with early progressive loss of motor skills, dementia,
blindness, macrocephaly and cherry-red retinal spots.
juvenile-onset -
dementia and ataxia, with death at age 10-15.
adult form has - clumsines s in childhood and motor weakness in adolescence.
Tay-Sachs disease (gangliosidosis),